Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification

Trial Profile

Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2016 Results assessing safety in comparison with historical controls (n=73) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 23 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jul 2013 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top